-
EP3580568
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3580568
| EP3580568 - BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 01.03.2024 Database last updated on 14.11.2024 | |
| Former | Examination is in progress Status updated on 17.09.2021 | ||
| Former | Request for examination was made Status updated on 15.11.2019 | ||
| Former | The international publication has been made Status updated on 18.08.2018 | ||
| Former | unknown Status updated on 09.03.2018 | Most recent event Tooltip | 01.03.2024 | Application deemed to be withdrawn | published on 03.04.2024 [2024/14] | Applicant(s) | For all designated states Fred Hutchinson Cancer Center 1100 Fairview Avenue North Seattle, WA 98109 / US | For all designated states The University of Washington 4545 Roosevelt Way NE Suite 400 Seattle, Washington 98105 / US | For all designated states Bloodworks Northwest 921 Terry Avenue Seattle, WA 98104 / US | [2022/24] |
| Former [2019/51] | For all designated states Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North Seattle, WA 98109 / US | ||
| For all designated states The University of Washington 4545 Roosevelt Way NE Suite 400 Seattle, Washington 98105 / US | |||
| For all designated states Bloodworks Northwest 921 Terry Avenue Seattle, WA 98104 / US | Inventor(s) | 01 /
LILES, W., Conrad 1412 Grand Avenue Seattle WA 98122 / US | 02 /
TURTLE, Cameron, J. 2918 1st Avenue N. Seattle WA 98109 / US | 03 /
MALONEY, David, G. 24216 SE 47th Street Issaquah WA 98902 / US | 04 /
RIDDELL, Stanley, R. 1763 268th Place SE Sammamish WA 98075 / US | 05 /
WURFEL, Mark, M. 2535 34th Avenue S. Seattle WA 98144 / US | 06 /
LOPEZ, Jose 539 32nd Avenue S. Seattle WA 98144 / US | 07 /
CHUNG, Dominic 17078 NE 37th Place Bellevue WA 98008 / US | 08 /
CHEN, Junmei 1210 15th Avenue E. Apt 228 Seattle WA 98112 / US | [2019/51] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2019/51] | Application number, filing date | 18707487.7 | 09.02.2018 | [2019/51] | WO2018US17655 | Priority number, date | US201762456798P | 09.02.2017 Original published format: US 201762456798 P | US201762544709P | 11.08.2017 Original published format: US 201762544709 P | [2019/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018148567 | Date: | 16.08.2018 | Language: | EN | [2018/33] | Type: | A1 Application with search report | No.: | EP3580568 | Date: | 18.12.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.08.2018 takes the place of the publication of the European patent application. | [2019/51] | Search report(s) | International search report - published on: | EP | 16.08.2018 | Classification | IPC: | G01N33/574 | [2019/51] | CPC: |
G01N33/57484 (EP,US);
C07K16/22 (US);
C07K16/248 (US);
G16B40/10 (US);
G16H50/30 (US);
G01N2333/515 (EP,US);
Y02A90/10 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/51] | Title | German: | BIOMARKER UND VERWENDUNGEN DAVON ZUR AUSWAHL VON IMMUNTHERAPIEINTERVENTIONEN | [2019/51] | English: | BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION | [2019/51] | French: | BIOMARQUEURS ET LEURS UTILISATIONS PERMETTANT LA SÉLECTION D'UNE INTERVENTION D'IMMUNOTHÉRAPIE | [2019/51] | Entry into regional phase | 28.08.2019 | National basic fee paid | 28.08.2019 | Designation fee(s) paid | 28.08.2019 | Examination fee paid | Examination procedure | 28.08.2019 | Examination requested [2019/51] | 28.08.2019 | Date on which the examining division has become responsible | 27.03.2020 | Amendment by applicant (claims and/or description) | 20.09.2021 | Despatch of a communication from the examining division (Time limit: M06) | 30.03.2022 | Reply to a communication from the examining division | 04.07.2023 | Despatch of a communication from the examining division (Time limit: M04) | 15.11.2023 | Application deemed to be withdrawn, date of legal effect [2024/14] | 05.12.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2024/14] | Fees paid | Renewal fee | 27.02.2020 | Renewal fee patent year 03 | 25.02.2021 | Renewal fee patent year 04 | 25.02.2022 | Renewal fee patent year 05 | 27.02.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI] - XINQI WU ET AL, "Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy", CANCER IMMUNOLOGY RESEARCH, US, (20170101), vol. 5, no. 1, doi:10.1158/2326-6066.CIR-16-0206, ISSN 2326-6066, pages 17 - 28, XP055462687 [X] 1,47 * abstract * [I] 2-19,26,27,30,48-53 DOI: http://dx.doi.org/10.1158/2326-6066.CIR-16-0206 | [XI] - D. C. GALLAGHER ET AL, "Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2-Induced Vascular Leak", CLINICAL CANCER RESEARCH, (20070401), vol. 13, no. 7, doi:10.1158/1078-0432.CCR-06-2509, ISSN 1078-0432, pages 2115 - 2120, XP055051315 [X] 1,47 * abstract * [I] 2-19,26,27,30,48-53 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-06-2509 | [A] - Lg Thijs ET AL, "Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects", The Journal of Immunology, UNITED STATES, (19900315), pages 2419 - 2424, URL: http://www.jimmunol.org/content/144/6/2419.full.pdf, XP055462673 [A] 1-19,26,27,30,47-53 * abstract * | [XI] - K. ANARGYROU ET AL, "Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, IT, (20080301), vol. 93, no. 3, doi:10.3324/haematol.11852, ISSN 0390-6078, pages 451 - 454, XP055482128 [X] 1,47 * abstract * [I] 2-19,26,27,30,48-53 DOI: http://dx.doi.org/10.3324/haematol.11852 | [XPI] - Kevin A Hay ET AL, "Regular Article IMMUNOBIOLOGY AND IMMUNOTHERAPY", doi:10.1182/blood-2017-06-, (20171123), URL: http://www.bloodjournal.org/content/bloodjournal/130/21/2295.full.pdf, (20180607), XP055482124 [XP] 1,47 * (p 2305, col 2, para 2)(p 2302, col 1, para 1) * [I] 2-19,26,27,30,48-53 DOI: http://dx.doi.org/10.1182/blood-2017-06- | [XP] - JULIANE GUST ET AL, "Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells", CANCER DISCOVERY, (20170309), vol. 7, no. 12, doi:10.1158/2159-8290.CD-17-0698, ISSN 2159-8274, pages 1404 - 1419, XP055462614 [XP] 1-19,26,27,30,47-53 * page 1411, column 1, paragraph 1 * DOI: http://dx.doi.org/10.1158/2159-8290.CD-17-0698 | by applicant | WO9709433 | WO2015095895 | - DAVILA et al., Sci. Transl. Med., (20140000), vol. 6, page 224ra25 | - KOCHENDERFER et al., J. Clin. Oncol., (20150000), vol. 33, page 540 | - MAUDE et al., N. Engl. J. Med., (20140000), vol. 371, page 1507 | - PORTER et al., Sci. Transl. Med., (20150000), vol. 7, page 303ra139 | - TURTLE et al., J. Clin. Invest., (20160000), vol. 126, page 2123 | - TURTLE et al., Sci. Transl. Med., (20160000), vol. 8, page 355ra116 | - TURTLE et al., Clin. Pharmacol. Ther., (20160000), vol. 100, page 252 | - BRUDNO; KOCHENDERFER, Blood, (20160000), vol. 727, page 3321 | - LEE et al., Blood, (20140000), vol. 124, page 188 | - LOCKE et al., Mol Ther., (20170000), vol. 25, page 285 | - BRENTJENS et al., Blood, (20110000), vol. 118, page 4817 | - PORTER et al., N. Engl. J. Med., (20110000), vol. 365, page 725 | - BRUDNO; KOCHENDERFER, Blood, (20160000), vol. 127, page 3321 | - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, page 403 | - ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, page 3389 | - LEHNINGER, Biochemistry, Worth Publishers, Inc., (19750000), pages 71 - 77 | - LEWIN, Genes IV, Oxford University Press, NY and Cell Press, Cambridge, MA, (19900000), page 8 | - CHO et al., Proc. Nat'l. Acad. Sci. USA, (20040000), vol. 707, page 5547 | - ALFIERI et al., Crit. Care, (20120000), vol. 76, page R182 | - HUANG et al., Int. J. Oncol., (20090000), vol. 34, page 79 | - KIM et al., Biochim. Biophys. Acta, (20090000), vol. 1793, page 772 | - CHUNG et al., Blood, (20160000), vol. 727, pages 637 - 645 | - WU et al., J. Thromb. Haemost., (20060000), vol. 4, page 129 | - PAGE; LILES, Virulence, (20130000), vol. 4, pages 507 - 516 | - SCHWAMEIS et al., Thromb. Haemost., (20150000), vol. 113, pages 708 - 718 | - YARLAGADDA et al., Psychiatry, (20090000), vol. 6, pages 18 - 22 | - ARMULIK et al., Nature, (20100000), vol. 468, pages 557 - 561 | - RUSTENHOVEN et al., Trends Pharmacol. Sci., (20170000), vol. 38, pages 291 - 304 | - TEACHEY et al., Cancer Dis., (20160000), vol. 6, page 664 | - MIKACENIC et al., PLoS One, (20150000), vol. 10, pages 1 - 13 | - PAGE; LILES, Virulence, (20140000), vol. 4, page 507 | - PAGE et al., J. Infect. Dis., (20130000), vol. 208, page 929 | - PAGE et al., Clin. Infect. Dis., (20110000), vol. 52, page e157 | - RICCIUTO et al., Crit. Care Med., (20110000), vol. 39, page 1 | - LOVEGROVE et al., PLoS One, (20090000), vol. 4, page e4912 |